These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 9797205)

  • 1. Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci.
    González I; Georgiou M; Alcaide F; Balas D; Liñares J; de la Campa AG
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2792-8. PubMed ID: 9797205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
    Jorgensen JH; Weigel LM; Ferraro MJ; Swenson JM; Tenover FC
    Antimicrob Agents Chemother; 1999 Feb; 43(2):329-34. PubMed ID: 9925527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
    Pan XS; Fisher LM
    J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.
    Pan XS; Ambler J; Mehtar S; Fisher LM
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2321-6. PubMed ID: 8891138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
    Pan XS; Fisher LM
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2810-6. PubMed ID: 9797208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.
    Muñoz R; De La Campa AG
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2252-7. PubMed ID: 8891124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci.
    Kaneko A; Sasaki J; Shimadzu M; Kanayama A; Saika T; Kobayashi I
    J Antimicrob Chemother; 2000 Jun; 45(6):771-5. PubMed ID: 10837428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci.
    Ferrándiz MJ; Oteo J; Aracil B; Gómez-Garcés JL; De La Campa AG
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2520-3. PubMed ID: 10508036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
    J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis.
    Janoir C; Podglajen I; Kitzis MD; Poyart C; Gutmann L
    J Infect Dis; 1999 Aug; 180(2):555-8. PubMed ID: 10395882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.
    Tankovic J; Perichon B; Duval J; Courvalin P
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2505-10. PubMed ID: 8913454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes.
    Taba H; Kusano N
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2193-6. PubMed ID: 9736534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in topoisomerase genes of fluoroquinolone-resistant salmonellae in Hong Kong.
    Ling JM; Chan EW; Lam AW; Cheng AF
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3567-73. PubMed ID: 14576119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the mechanisms of quinolone resistance in clinical isolates of Citrobacter freundii.
    Navia MM; Ruiz J; Ribera A; de Anta MT; Vila J
    J Antimicrob Chemother; 1999 Dec; 44(6):743-8. PubMed ID: 10590274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae.
    Balsalobre L; Ferrándiz MJ; Liñares J; Tubau F; de la Campa AG
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2072-81. PubMed ID: 12821449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoroquinolone resistance in atypical pneumococci and oral streptococci: evidence of horizontal gene transfer of fluoroquinolone resistance determinants from Streptococcus pneumoniae.
    Ip M; Chau SS; Chi F; Tang J; Chan PK
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2690-700. PubMed ID: 17548487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.
    Ferrándiz MJ; Fenoll A; Liñares J; De La Campa AG
    Antimicrob Agents Chemother; 2000 Apr; 44(4):840-7. PubMed ID: 10722479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa.
    Mouneimné H; Robert J; Jarlier V; Cambau E
    Antimicrob Agents Chemother; 1999 Jan; 43(1):62-6. PubMed ID: 9869566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
    Akasaka T; Tanaka M; Yamaguchi A; Sato K
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2263-8. PubMed ID: 11451683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.